Skip to content
HealthTech Series A Founded 2016

Iktos

Iktos offers artificial intelligence for new drug design. The company is using artificial intelligence technology for ligand-based de novo drug design and focusing on multiparametric optimization (MPO). Their platform can design new, druggable and synthesizable molecules according to particular criteria. Their technology is based on deep learning algorithms. The company was founded in 2016 and headquartered in…

📍 Paris, France · Life Sciences Tech,

Funding snapshot

Last roundSeries A
Amount$16M
Date9 March 2023
Total raised$16M
Team size67

About

Iktos offers artificial intelligence for new drug design. The company is using artificial intelligence technology for ligand-based de novo drug design and focusing on multiparametric optimization (MPO). Their platform can design new, druggable and synthesizable molecules according to particular criteria. Their technology is based on deep learning algorithms. The company was founded in 2016 and headquartered in Paris, France. It has raised $16.3M in series a funding, with backing from M Ventures, Debiopharm, Omnes Capital. The company operates in the HealthTech - Life Sciences Tech, Life Sciences - Life Sciences Tech, Native AI - Artificial Intelligence space. Its offerings span Oncology - Drugs - Pan Cancer and Metabolic Diseases - Drugs - Obesity.

Business model

Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics > Lead Discovery > AI Based,

Oncology > Drugs > Pan Cancer,

Metabolic Diseases > Drugs > Obesity,

Obesity > Drugs,

Immunology > Drugs > Diversified

Founders & team highlights

Serial Founder

Institutional investors

M Ventures Debiopharm Omnes Capital

Latest coverage

No articles yet.

Raising like Iktos?

Analyze your pitch deck before your next raise.

Analyze My Deck →